🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Prestige Consumer Healthcare Inc. PBH R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.prestigebrands.com

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

READ MORE ›
$47.53
-44.52% 1Y

Market & Price

Market Cap
$2.25B
Current Price
$47.53
High / Low (52W)
$86.64 / $45.93
Beta
0.40

Valuation

Stock P/E
12.16
Industry PE
23.65
Forward P/E
9.37
PEG Ratio
1.44
Book Value
$38.66
Price to Book
1.23
P/S
2.07
EV/EBITDA
9.49
Dividend Yield
-

Profitability & Returns

ROCE
8.89%
ROE
10.22%
ROA
5.61%
Profit Margin
17.48%
Op Margin
26.81%
EPS (Latest Qtr)
$0.97
EPS (TTM)
$3.91

Balance Sheet & Liquidity

Debt/Equity
0.55
Quick Ratio
2.12
Current Ratio
3.57
Debt
$1.05B
Total Assets
$3.49B
Current Assets
$431.48M
Working Capital
$310.56M

Ownership

Promoter Holding
1.41%
Chg in Prom Hold
-
FII / Inst Holding
113.42%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$3.23B
Total Revenue (TTM)
$1.09B
EBITDA
$340.68M
Free Cash Flow
$192.76M
Operating Cash Flow
$257.63M
Shares Outstanding
47.37M
Gross Margin
55.65%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-1.17%
Profit 5Y
110.40%
Revenue (YoY)
-5.00%
Earnings (YoY)
12.40%

PROS

  • Profit CAGR of 110.4% over 5 years.
  • Generates positive free cash flow.

CONS

  • Revenue declined at -1.2% CAGR over 5 years.
  • Trading 45.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PBH Prestige Consumer Healthcare Inc. R2K 47.53 12.16 $2.25B - 8.89% 10.22% -1.17% 110.40%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Jun 2021Sep 2021Dec 2021Jun 2022Sep 2022Dec 2022Jun 2023Sep 2023Dec 2023Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------256.57M258.03M270.62M255.97M253.98M239.36M241.41M241.03M232.15M238.07M241.55M251.24M229.39M237.42M238.79M269.18M276.23M274.47M277.06M289.27M275.52M279.31M286.32M282.74M267.14M283.79M-296.52M249.53M274.11M283.44M281.62M
Cost of Revenue -----------------------------------126.51M109.20M122.53M126.08M135.32M
Gross Profit 112.24M119.94M116.78M118.25M121.59M123.97M124.55M130.18M143.48M144.10M147.67M141.26M140.62M137.47M139.24M138.25M134.07M136.75M137.50M143.91M133.87M137.66M138.89M159.01M157.71M155.06M160.12M161.01M150.40M154.67M160.02M157.94M146.02M157.38M-170.01M140.33M151.58M157.37M146.30M
Operating Expenses -----------------------------------69.12M68.58M71.91M74.88M70.81M
Operating Income 62.51M69.90M62.64M65.27M12.21M71.06M69.29M53.05M78.95M75.72M83.89M-23.10M72.49M70.92M77.54M-153.45M71.49M69.35M76.40M73.92M80.12M72.90M73.44M91.34M78.56M82.59M87.01M84.38M87.18M85.19M88.25M86.83M72.05M84.34M-100.89M71.76M79.67M82.49M75.49M
EBITDA -----------------------------------91.97M79.65M86.83M80.08M84.55M
Interest Expense -----------------------------------10.76M10.20M10.04M10.67M11.43M
Pretax Income -----------------------------------73.96M61.78M69.13M61.81M64.77M
Tax Provision -----------------------------------23.83M14.31M26.92M15.12M10.84M
Net Income 26.17M31.80M28.00M13.94M-5.53M32.20M31.64M11.09M33.76M30.70M314.79M-39.69M34.47M30.84M38.17M-139.27M33.92M33.25M38.06M37.05M43.71M44.59M40.87M57.76M45.33M50.22M55.27M51.02M51.95M53.28M53.56M53.05M49.07M54.38M-50.13M47.47M42.21M46.70M53.93M
Diluted EPS 0.490.600.530.26-0.100.600.590.210.630.575.88-0.750.650.590.73-2.680.650.650.750.730.860.880.811.140.890.991.091.021.041.061.071.060.981.091.221.000.950.860.97-

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -------882.06M1.04B975.78M963.01M943.37M-1.13B1.13B1.14B1.09B
Cost of Revenue -------------502.43M500.91M503.30M493.13M
Gross Profit 153.44M170.88M227.38M343.74M335.55M406.22M467.21M500.29M576.50M555.58M552.22M547.47M-625.29M624.45M634.46M595.58M
Operating Expenses -------------277.49M282.02M285.22M286.17M
Operating Income 78.33M76.14M102.82M191.88M188.62M207.56M260.31M205.64M215.47M67.50M291.15M297.40M-347.80M342.43M349.24M309.41M
EBITDA -------------7.87M373.86M361.99M331.11M
Interest Expense -------------69.16M67.16M47.63M42.34M
Pretax Income --------------93.92M276.02M284.19M257.50M
Tax Provision --------------11.61M66.69M69.58M67.19M
Net Income 32.12M29.22M37.21M65.50M72.61M78.26M99.91M69.39M339.57M-35.80M142.28M164.68M--82.31M209.34M214.60M190.30M
Diluted EPS 0.640.580.731.271.391.491.881.306.34-0.692.783.254.04-1.654.174.29-

Compounded Sales Growth

5 Years:-1.17%
1 Year:-5.00%

Compounded Profit Growth

5 Years:110.40%
1 Year:12.40%

Stock Price Performance

1 Year:-44.52%
6 Months:-19.45%
3 Months:-31.41%
1 Month:-15.16%

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets --1.06B1.76B1.74B1.80B2.64B2.95B3.91B3.76B3.44B3.51B3.43B-3.35B3.32B3.40B3.49B
Current Assets --------------391.74M375.04M448.33M431.48M
Cash & Equivalents 35.18M41.10M13.33M19.02M15.67M28.33M21.32M27.23M41.85M32.55M27.53M94.76M32.30M-58.49M46.47M97.88M63.87M
Inventory --------------162.12M138.72M147.71M159.13M
Receivables --------------183.37M185.03M202.04M208.57M
Total Liabilities --695.09M1.36B1.26B1.23B2.01B2.20B3.09B2.58B2.35B2.34B2.07B-1.91B1.66B1.57B1.61B
Current Liabilities --54.21M63.92M96.67M84.36M99.04M106.68M162.01M123.20M126.98M149.88M122.14M-160.72M117.05M106.62M120.92M
Long Term Debt --486.94M1.12B970.90M934.41M1.56B1.63B2.19B1.99B1.80B1.73B1.48B-1.35B1.13B992.36M993.95M
Total Debt --------------1.37B1.14B1.04B1.05B
Total Equity 294.38M329.06M361.83M402.73M477.94M563.36M627.62M744.34M822.55M1.18B1.10B1.17B1.36B-1.45B1.66B1.83B1.89B
Shares Outstanding --------------54.86M55.50M56.01M56.21M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 59.43M86.67M67.45M137.60M111.58M156.25M176.31M148.67M210.11M189.28M217.12M235.61M-229.72M248.93M251.51M257.63M
Investing Cash Flow 7.32M-275.68M-662.21M11.22M-57.98M-805.26M-222.97M-694.60M-11.56M55.43M-16.57M-22.24M--11.58M-20.11M-17.45M-136.84M
Financing Cash Flow -60.83M161.25M600.43M-152.12M-41.15M643.26M52.08M560.96M-208.96M-249.33M-131.43M-279.42M--185.85M-241.01M-182.07M-156.06M
Capital Expenditure -673.00K-655.00K-606.00K-10.27M-2.76M-6.10M-3.57M-2.98M-12.53M-10.48M-14.56M-22.24M--7.78M-9.55M-8.22M-11.18M
Free Cash Flow 58.75M86.02M66.85M127.34M108.82M150.15M172.74M145.69M197.58M178.80M202.56M213.36M-221.93M239.38M243.29M246.45M
Net Change in Cash -------------32.29M-12.20M51.99M-35.28M
Share Buybacks -------0049.98M56.72M11.87M050.00M25.00M51.51M156.28M

Ratios (Annual)

Figures in %.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -------56.7%55.4%56.9%57.3%58.0%-55.4%55.5%55.8%54.7%
Operating Margin % -------23.3%20.7%6.9%30.2%31.5%-30.8%30.4%30.7%28.4%
Net Margin % -------7.9%32.6%-3.7%14.8%17.5%--7.3%18.6%18.9%17.5%
ROE % 9.8%8.1%9.2%13.7%12.9%12.5%13.4%8.4%28.8%-3.3%12.2%12.1%--5.7%12.6%11.7%10.1%
ROCE % -7.6%6.1%11.7%11.0%8.2%9.2%5.5%5.9%2.0%8.7%9.0%-10.9%10.7%10.6%9.2%

Shareholding Pattern

Insiders
1.41%
Institutions
113.42%
Public Float
115.04%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 15.60% 7.39M $351.17M
2 Ariel Investments, LLC 9.02% 4.27M $203.16M
3 Vanguard Portfolio Management LLC 5.92% 2.80M $133.27M
4 Dimensional Fund Advisors LP 5.64% 2.67M $127.04M
5 Kayne Anderson Rudnick Investment Management LLC 4.65% 2.20M $104.69M
6 Vanguard Capital Management LLC 4.42% 2.09M $99.48M
7 State Street Corporation 4.16% 1.97M $93.68M
8 Allspring Global Investments Holdings, LLC 3.29% 1.56M $74.06M
9 Geode Capital Management, LLC 3.08% 1.46M $69.40M
10 Morgan Stanley 2.87% 1.36M $64.52M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PBH

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks